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The nuclear receptor REV-ERB plays an important role in a range of physiological processes. REV-ERB behaves as a ligand-dependent transcriptional
repressor and heme has been identiﬁed as a physiological agonist. Our current
understanding of how ligands bind to and regulate transcriptional repression
by REV-ERB is based on the structure of heme bound to REV-ERB. However,
porphyrin (heme) analogues have been avoided as a source of synthetic agonists due to the wide range of heme binding proteins and potential pleotropic
effects. How non-porphyrin synthetic agonists bind to and regulate REV-ERB
has not yet been deﬁned. Here, we characterize a high afﬁnity synthetic REVERB agonist, STL1267, and describe its mechanism of binding to REV-ERB as
well as the method by which it recruits transcriptional corepressor both of
which are unique and distinct from that of heme-bound REV-ERB.
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The nuclear receptor REV-ERB is a component of the molecular clock
that regulates the rhythmic expression of inﬂammatory1–4, metabolic5,6,
and cellular proliferative genes7–10. Genes directly regulated by either
REV-ERB, REV-ERBα [NR1D1] or REV-ERBβ [NR1D2], are typically transcriptionally silenced by the receptors. This is due to REV-ERB functioning as a ligand-dependent transcriptional repressor with heme as
the endogenous ligand11,12. Heme is present in all cells at a concentration
that allows REV-ERB to maintain a basal level of repression of target
genes providing the appearance of constitutive transcriptional repressor that was initially prescribed to it prior to the discovery of heme as a
ligand. REV-ERBs are particularly efﬁcacious transcriptional repressors,
and they lack the carboxy-terminal activation function 2 domain
required for coactivator protein recruitment. Thus, REV-ERBs display a
particularly strong level of recruitment of the corepressor NCoR. REVERBs have been demonstrated to play a role in a range of disease states
suggesting that agonists may be useful in treating diseases associated
with inﬂammation, metabolic dysfunction, and cancer13.
The REV-ERB LBD displays the canonical NR structure composed
of a three-layered α-helical sandwich, and heme binds in the

prototypical ligand binding pocket of the LBD. Quite interestingly, the
iron atom within the protoporphyrin ring is coordinated by histidine
and cysteine residues that are conserved in both REV-ERBα and REVERBβ14,15. These two residues had previously been predicted to play
such a role in heme binding to REV-ERB and mutation of either of these
residues leads to loss of heme binding and loss of transcriptional
repressor activity11,12. Most recent structural studies have demonstrated that heme binding drives cooperative binding of NCoR interaction domain (ID) peptides to the REV-ERB LBD providing the
molecular mechanism for ligand-dependent transcriptional repression
by REV-ERB15.
Heme is an endogenous ligand for REV-ERB11,12, but since heme
binds to many types of proteins, speciﬁcity concerns prevent its
structure from being used as starting point for synthetic ligand
development. The ﬁrst synthetic ligand to REV-ERB was discovered
through a ﬂuorescence resonance energy transfer (FRET) assay
showing that a compound increased binding of nuclear co-repressor
NR interaction domain 1 (NCoR ID1) to REV-ERBα ligand binding
domain (LBD) in a concentration-dependent manner16. This initial
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synthetic REV-ERB agonist, GSK4112, has low potency and efﬁcacy as
well as very poor systemic exposure in vivo providing only limited
utility as a chemical tool to probe REV-ERB function. Our lab as well as
others attempted to improve the pharmacological properties of
GSK4112 in order to provide REV-ERB chemical tools with more
favorable properties. One of the identiﬁed compounds was SR90096.
This compound displayed improved potency for REV-ERBα and REVERBβ over GSK4112 and speciﬁcity for REV-ERB over the other 46
human nuclear receptors. SR9009 is three to four times more potent
and three times more efﬁcacious than GSK4112 in a cell-based
cotransfection assay, and it also has increased systemic exposure,
including the ability to cross the blood-brain barrier13. SR9009 has now
become the most widely published tool compound for modulating
REV-ERB both in cell culture and in vivo.
Although SR9009 and structurally related compounds are useful
chemical tools for research, this scaffold is less than ideal due to
concerns about relatively poor potency, lack of bioavailablity, potential toxicity, and arguably, speciﬁcity. In addition, SR9009 and almost
all its analogs contain a nitrothiophene group, which is considered a
toxicity liability13. A recent study has questioned the speciﬁcity of
SR9009, calling into question the results from numerous studies using
this tool compound to modulate the REV-ERB nuclear receptor17. Thus,
a scaffold for REV-ERB agonists, one with greater potency, less toxicity,
and unquestionable speciﬁcity is needed.
Here, we describe the activity of a synthetic REV-ERB agonist with
a distinct chemical scaffold relative to SR9009 with improved potency
and reduced cell toxicity. Furthermore, we deﬁne how the synthetic
agonist binds within the ligand binding domain (LBD) of REV-ERB by
analyzing the co-crystal structure of the agonist, STL1267, within the
LBD of REV-ERBα.

Our previous work on the structure activity relationship of GSK4112/
SR9009 chemical scaffold (Fig. 1a) as well as that of others18–20, led us
to seek other scaffolds that would provide improved properties.
Utilization of heme as a REV-ERB ligand in various biochemical assays
is limited due to its chemical-physical properties15 and SR9009 analogues also did not provide optimal performance for the development of radioligand binding assays or for the determination of
cocrystal structures with REV-ERB to assess the mechanism of synthetic agonist binding to the receptor. We noted a recent patent that
described a series of REV-ERB agonists (6-substituted[1,2,4]triazolo[4,3-b]pyridazines) in assays that detected the ability of small
molecules to enhance the interaction of REV-ERBα with NCoR either
in biochemical or cell-based assays21. One of these compounds (we
termed as STL1267; Fig. 1b; Supplementary Fig. 1, synthesis scheme
can be found in Supplementary Methods), displayed potency of
~0.1–0.3 μM in these assays and we decided to characterize it more
fully as shown below. A FRET assay that detects agonist-dependent
recruitment of NCoR ID1 CoRNR box to the REV-ERBα-LBD was utilized to compare the activity of STL1267 to SR9009 (Fig. 1c). We
observed dose-dependent recruitment of NCoR peptide with
increasing amounts of either STL1267 or SR9009. The efﬁcacy of
NCoR ID1 recruitment in the presence of STL1267 was roughly double
that of SR9009, and the potency of STL1267 (EC50 = 0.13 μM) was
more than ten times greater than SR9009 (EC50 = 1.9 μM) (Fig. 1c).
The high potency of STL1267 led us to consider the development of a
radioligand binding assay that would detect direct binding of ligands
to the LBD of REV-ERBα and REV-ERBβ.

Fig. 1 | STL1267 binds to REV-ERB, resulting the recruitment of NCoR and
regulation of downstream target genes. Structures of SR9009 (a) and STL1267
(b). c FRET assay demonstrating NCoR ID1 recruitment to REV-ERBα in the
presence of STL1267 (λ; blue) or SR9009 (ν; light blue). Results of a REV-ERBα
scintillation proximity radioligand binding assay illustrating displacement
curves using either unlabeled STL1267 (d) or SR9009 (e) to displace
3
H-STL1267 from the REV-ERBα LBD. f Cell-based two-hybrid luciferase

reporter assay demonstrating the ability of either STL1267 (○; light blue) or
SR9009 (□; blue) to drive recruitment of NCoR1 by REV-ERBα dose-dependently. HEK-UAS-luc reporter cells were co-transfected with NCoR-Vp16 and
REV-ERBα-FL/GAL4-DBD constructs. Data are presented as mean ± SEM for
c, d and e and mean ± SD for f. Each point in the biochemical and cell-based
experiments represent triplicate determinations and experiments were typically repeated 3 times.

Nature Communications | (2022)13:7131

STL1267 binds directly to the ligand binding domain (LBD) of
REV-ERB

2

Article

https://doi.org/10.1038/s41467-022-34892-4

Fig. 2 | STL1267 regulates REV-ERB target genes in cell-based assays. a HepG2
cells treated with DMSO (blue), SR9009 (purple) or STL1267 (light blue) for 24 h
(n = 3 to 8) followed by assessment of cell viability by crystal violet staining.
DMSO vs. 10 μM SR9009. b Proliferating C2C12 cells treated with DMSO (blue)
SR9009 (purple) or STL1267 (light blue) for 24 h (n = 3 to 8) followed by assessment of cell viability by crystal violet staining. (DMSO vs. 10 μM SR9009
P = 0.0003; DMSO vs. 20 μM SR9009 P < .0001; DMSO vs. 20 μM STL1267
P = 0.0481). c Expression of BMAL1 in HepG2 cells in response to 24 h treatment
with DMSO (blue), 5 μM STL1267 (purple) or SR9009 (light blue) (n = 4)
P = 0.0010 vehicle vs. STL1267, P = 0.0009 vehicle vs. SR9009. Relative gene
expression in C2C12 cells (n = 3) in response to REV-ERB agonist treatment (5 μM)

was assessed for mitochondrial complex genes (Mt-Nd1 – DMSO vs. SR9009
P = 0.0024 and vs. STL1267 P = 0.0001; Mt-Co1 – DMSO vs. STL1267 P = 0.0005)
(d), fatty acid oxidation (Vlcad – DMSO vs. SR9009 P = 0.062 and vs. STL1267
P = 0.0074; Lcad – DMSO vs. SR9009 P = 0.0209 and vs. STL1267 P = 0.007; Scad
– DMSO vs. SR9009 P = 0.0374 and vs. STL1267 P = 0.0030) (e), and mitochondrial function/biogenesis (Lkb1 – DMSO vs. STL1267 P = 0.0316; Sirt1 – DMSO vs.
STL1267 P = 0.0600; Ppargca1 – DMSO vs. SR9009 P = 0.0015 and vs. STL1267
P = 0.0012; Nampt – DMSO vs. SR9009 P = 0.0338 and vs. STL1267 P = 0.0542)
(f). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 vs DMSO or vehicle control
by one-way ANOVA followed by Dunnett’s post hoc test. Data are presented as
mean ± SEM. Source data are available as a Source Data ﬁle.

Using custom tritiated STL1267 we performed a scintillation
proximity assay (SPA) with beads bound to the REV-ERBα LBD. The
beads were saturated with radioligand, 3H-STL1267, and this tritiated
ligand was displaced with unlabeled ligand (STL1267 or SR9009).
Unlabeled STL1267 effectively displaced 3H-STL1267 from REV-ERBα
(Ki = 0.16 μM) forming a displacement curve indicating one single
binding site of STL1267 to REV-ERB (Fig. 1d). SR9009 also effectively
displaced 3H-STL1267 from REV-ERBα (Ki = 0.68 μM) (Fig. 1e) suggesting overlap in their binding sites. Due to the optical properties of
heme, we were unable to utilize this ligand in the radioligand
binding assay.

We next assessed the activity of STL1267 in a cell-based assay. We
utilized a chimeric construct expressing full length human REV-ERBα
(REV-ERBα-FL) fused to the DNA-binding domain (DBD) of yeast transcription factor GAL4. HEK293 cells stably expressing a GAL4 responsive luciferase reporter were co-transfected with REV-ERBα GAL4-DBD
and NCoR-Vp16. This format of the assay essentially functions as a
mammalian 2-hybrid assay and detects REV-ERB agonists as activators
of transcription effectively enhancing the sensitivity of such an assay
from the typical one hybrid system that detects enhancement of
transcriptional repression. We again compared STL1267 to SR9009 in
this assay, and as illustrated in Fig. 1f, STL1267 displayed enhanced
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Fig. 3 | Crystal structure of STL1267 bound to the ligand binding domain of
REV-ERBα. a Crystal structure of STL1267 bound to the ligand binding domain of
REV-ERBα with NCoR ID1. REV-ERBα is illustrated in green ribbons and NCoR ID1 in
purple ribbons. The ligand is shown as ball and stick representation. Common
structural components (α helices) within the nuclear receptor LBD are designated.
b Close-up view of STL1267 binding within the ligand binding pocket of REV-ERBα.
The ligand is illustrated as purple stick representation and the protein amino side

chains are demonstrated by green stick representation. Hydrophobic amino acids
stabilize STL1267 in the ligand binding pocket of REV-ERBα. c 2D diagram illustrating STL1267 interactions with amino acid residues within the ligand binding
pocket of REV-ERBα. The label A corresponds to the REV-ERB protein residues while
label B corresponds to the NCOR residues. (d) 2fo − fc electron density map around
ST1267 contoured at 2σ.

potency and efﬁcacy relative to SR9009. STL1267 displayed an EC50 of
1.8 μM vs. 4.7 μM for SR9009. The maximal efﬁcacy for recruitment of
NCoR-VP16 was ~8-fold greater for STL1267 vs. SR9009.
We assessed the speciﬁcity of STL1267 using both in house
nuclear receptor Gal4-NR reporter assays and the NIMH Psychoactive
Drug Screening Program (PDSP) assays. We assessed the speciﬁcity of
STL1267 in the PDSP’s radioligand displacement assays, screening for
binding to off-target GPCRs, ion channels, transporters, and other
drug targets (Table S1). Of the 43 targets assessed in this panel, we
observed no detectable binding in 41 of them. We detected weak
binding to the serotonin transporter (Ki ~ 2–4 μM). The kappa opioid
receptor also displayed activity in the binding assay with a Ki of
0.72 μM, but this is clearly not as high afﬁnity as STL1267 has for REVERB. Additional assessment in serotonin transporter and kappa opioid
receptor activity in a functional assay may be warranted to determine
absolute speciﬁcity. We did not detect activity of STL1267 against a
range of NRs including AR, GR, MR, PR, ERα, ERβ, TRα, LXRα, RARα,
RXRα, FXR, and VDR (Table S1) using a cotransfection assay as previously described22–24.
Together, these data indicate direct binding of STL1267 to REVERBα, followed by NCoR recruitment. STL1267 binds more potently to
REV-ERBα than SR9009 and appears to recruit corepressor more

efﬁcaciously. In addition, the speciﬁcity proﬁle of STL1267 is very
favorable with no activity at a range of other ligand-regulated NRs and
minimal binding at other classes of receptors/transporters.

Nature Communications | (2022)13:7131

STL1267 regulates expression of REV-ERB target genes
A relatively recent study indicated that SR9009 displays general
toxicity in cell-based assays17. Although we and others have not
observed this degree of toxicity2–4,6–8,25,26, we sought to compare the
effect of SR9009 to STL1267 on cell viability in two commonly used
cell lines. Cellular viability was tested in two cell types, human
hepatocarcinoma HepG2 cells and proliferating C2C12 mouse myoblast cells. In HepG2 cells, SR9009 had minimal effect on cell viability
(~10% reduction at 10 and 20 μM) while STL1267 showed no adverse
effects on cell viability up to the maximum dose examined (20 μM)
(Fig. 2a). Proliferating C2C12 cells were considerably more sensitive
with SR9009 displaying much greater reduction in cellular viability
(~25% reduction at 10 μM and ~50% at 20 μM) (Fig. 2b). In these cells,
STL1267 displayed a much more favorable proﬁle than SR9009
relative to reduction in viability (~10% reduction at 10 μM and ~20%
reduction at 20 μM). It is important to note that in both cell lines with
either drug, doses of 5 μM and below displayed no indication of
reduction in cellular viability.
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Fig. 4 | Schematic illustrating effects of STL1267 binding and comparison to
apo REV-ERBα and heme bound REV-ERBβ. a Overlay of the REV-ERBα/NCoR ID1/
STL1267 (protein is shown as green ribbons, NCoR peptide as blue ribbons and
ligand carbons are shown in purple) and REV-ERBα/NCoR ID1 (protein is shown as
orange ribbons, NCoR peptide as pink ribbons, PDB:3N00). b Detailed view of the
superimposed ligand binding pockets of both structures. Orange amino acid

residues corresponds to the apo REV-ERBα, green amino acid residues correspond
to the STL1267/REV-ERBα. The ligand is illustrated by purple carbons. c Overlay of
the REV-ERBα/STL1267 (purple) and REV-ERBβ/heme (yellow). d Detailed view of
STL1267 within the REV-ERBα LBD. Ligand is colored gray. e Detailed view of heme
within the REV-ERBβ LBD (heme is colored gray and the orange sphere
represents iron).

We next determined whether STL1267 can regulate characterized REV-ERB modulated genes in cell lines expressing REV-ERB
naturally. Five micromolar doses of both drugs were used in cellbased experiments from this point on. REV-ERB is an established
component of the core molecular clock repressing the expression of
core clock gene Bmal16,27 as well as others28,29. Using a human hepatocarcinoma cell line, HepG2, STL1267 attenuated the expression of
REV-ERB target gene and circadian modulator, Bmal1. In this assay,
STL1267 was more efﬁcacious than SR9009 in repressing Bmal1 gene
expression (Fig. 2c). In skeletal muscle, REV-ERB agonism increases
the expression of a wide variety of genes important in mitochondrial
function5. When proliferating mouse myoblast C2C12 cells were
treated with either REV-ERB agonist, expression of mitochondrial
complex (mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 - Mtnd1, mitochondrially encoded
cytochrome C oxidase I -Mtco1), fatty acid oxidation (very long chain
acyl-CoA dehydrogenase-Vlcad, long-chain acyl-CoA dehydrogenaseLcad, Short-chain acyl-CoA dehydrogenase-Scad), and mitochondrial
function/biogenesis (liver kinase B1-Lkb1, sirtuin 1-Sirt1, Nicotinamide phosphoribosyltransferase-Nampt, peroxisome proliferatoractivated receptor coactivator 1-Ppargc1a) genes were upregulated
(Fig. 2d–f). All of these genes were demonstrated to be responsive to
REV-ERB previously5. STL1267 was more efﬁcacious than SR9009 in
upregulating of several of these gene targets (Fig. 2c–f). These data
demonstrate that STL1267 modulates REV-ERB target genes in cellbased models and displays similar activity as SR9009 with the
exception that it appears to be more efﬁcacious in terms of maximal
gene regulation in many cases.

Characterization of STL1267 in vivo

Nature Communications | (2022)13:7131

To test the efﬁcacy of STL1267 in vivo, we began by assessing tissue
exposure following i.p. administration. We administered vehicle or
50 mg/kg of STL1267 via intraperitoneal injection to C57Bl/6 J mice.
The mice were sacriﬁced at four subsequent time points over the
next 12 h. The plasma half-life of STL1267 was ~1.6 h, and the compound was localized in all the tissues collected (brain, plasma,
liver, skeletal muscle, white adipose tissue) (Supplementary Fig. 2a).
Brain levels were similar to plasma levels indicating that
STL1267 successfully crosses the blood brain barrier (Supplementary
Fig. 2a). Given that we had good exposure following i.p. administration, we also assessed Bmal1 expression in liver at 12 h post administration and observed that STL1267 effectively suppressed Bmal1
expression consistent with its function as a REV-ERB agonist (Supplementary Fig. 2b). Together, these data suggest that STL1267 is a
valuable tool compound for studying REV-ERB function both in vitro
and in vivo.

Crystal structure of a synthetic agonist bound to the REVERBα LBD
Although the crystal structures of the apoREV-ERBα30 and -β31 LBDs
have been determined as well as the structure of natural porphyrins
(heme14,15 or cobalt protophorphyrin32) bound to REV-ERBβ, no structures of non-porphyrin, synthetic ligands bound to either REV-ERBs
have been described. Attempts to determine the structure of SR9009
bound to REV-ERB had failed and with the higher afﬁnity STL1267 in
hand, we sought to determine if this would aid in determination of a
structure.
5
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Fig. 5 | Distinct conformations of NCoR1 ID1 peptide binding to REV-ERB
induced by STL1267 vs heme. a Structure of STL1267/REV-ERBα LBD (yellow)
bound to NCoR1 ID1 peptide (purple). Regions of the receptor interacting with
NCoR are represented in gray. STL1267 is represented in space ﬁlled format.

b Structure of heme/REV-ERBβ LBD (yellow) bound to NCoR1 ID1 peptide (purple)
(PDB: 6WMQ). Regions of the receptor interacting with NCoR are represented in
gray. Heme is represented in space ﬁlled format.

We determined the crystal structure of a ternary complex
containing the REV-ERBα LBD bound to the corepressor NCoR ID1
CoRNR box peptide and the agonist STL1267 (Table S3). Except
for helix 12, which is naturally lacking in REV-ERBα, the overall
three-dimensional structure of REV-ERBα displays the canonical
architecture of nuclear receptor LBD with a three-layer α-helical
sandwich and two stranded β-sheets. The C-terminal of helix 11
assumes a well-deﬁned extended β-strand conformation allowing
for the formation of an antiparallel β-sheet interactions with
N-terminal residues of NCoR ID1. Besides the β-sheet interaction,
NCoR ID1 contains a carboxy-terminal four-turn helix (Fig. 3a)
that docks into the coregulator binding cleft of REV-ERBα LBD,
known as the AF-2 surface. The ligand resides in a predominantly
hydrophobic pocket where it makes primarily hydrophobic
interactions with the receptor. The triazolo-pyridazine group of
STL1267 efﬁciently ﬁlls the narrow portion of the hydrophobic
pocket and forms π-π stacking interactions with Phe484 and
Phe497 (Fig. 3b, c). We compared the structure of the REV-ERBα/
NCoR ID1/STL1267 complex with the previously solved structures
of the apo REV-ERBα/NCoR ID1 (PDB: 3N00)30 and REV-ERBβ/
Heme (PDB: 3CQV)14 complexes. The global receptor conformation of STL1267-bound REV-ERBα LBD was very similar to that of
the apo REV-ERBα (overall Cα RMSD of 1.07 Å) (Fig. 4a). However,

superposition of both structures indicates several differences in
the ligand binding pocket to accommodate ligand binding. First,
binding of STL1267 stabilized the β-sheet region (residues
Gln493-Gln506) through hydrophobic interactions with Phe497
and Leu498, which is disordered in the apo REV-ERBα structure
(Fig. 4b). Outward displacement of helix 3 and change of conformation of amino acid Met529, Phe439 and Phe443 were
observed, which provided space for ligand binding (Fig. 4b).
The binding mode of STL1267 differs substantially from heme
binding in the REV-ERB LBP14. Although the STL1267 structure is crystallized with REV-ERBα and the heme structures are crystallized with
REV-ERBβ, both REV-ERBα and REV-ERBβ have high degree of similarity
and the residues within REV-ERBβ demonstrated to interact with heme
are conserved in both isotype suggesting that heme-bound REV-ERBα
will have similar structural features to REV-ERBβ bound with heme
(Supplementary Fig. 3). Heme binds in a solvent exposed region in the
LBD near helix 11 where several water molecules observed in the LBP
make hydrogen bonds with the carboxylic groups of heme while its
central iron molecule is coordinated by residues His586 and Cys384 of
REV-ERBβ (Fig. 4c, e). There is minimal overlap between STL1267 and
heme in terms of the occupied space in the LBP. The binding of STL1267
is quite distinct from that of heme and where heme binds proximal to
helix 11, STL1267 binds distal to helix 11 and is deeply buried within a

Nature Communications | (2022)13:7131
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Fig. 6 | Mutational analysis of amino acid residues within the ligand binding
pocket of REV-ERBα. a Results of a two-hybrid reporter assay (Gal4-FL REV-ERBα/
NCoR1-VP16) assay illustrating the effects of mutation of amino acid residues that
interact with STL1267 within the ligand binding pocket. (WT ▾, F497A ●, F443A ■,
L480A ▲, F439A ♦, F484A ○, F488A □). Each point in the biochemical and cellbased experiments represent triplicate determinations and experiments were

typically repeated three times. Data are presented as mean ± SEM. b Overlay of the
ligand binding pockets of REV-ERBα/STL1267/NCoR ID1 complex before (green)
and after (blue) the MD simulations. c Distance probability distribution for STL1267
and selected amino acid residues (F497A yellow, F443A red, L480A black, F439A
purple, F484A blue, F488A green).

hydrophobic pocket surrounded by helices 3 and 5 and the
two β-sheets strands (Fig. 4c–e). Although the corepressor binding
surface of both heme- and STL-1267 bound REV-ERB LBD was preserved
with the α-helical region of the ID1 peptides containing the
I/LxxI/LI corepressor NR (CoRNR) box motif binding effectively, major
distinctions were observed in the mechanism of corepressor binding
between the two ligand-bound receptors. STL1267 binding induces an
antiparallel β-sheet formation between the amino-terminus of the NCoR
ID1 CoRNR box peptide and a β-strand extension of helix 11 (Fig. 5a),
which was not observed in the heme-bound receptor (Fig. 5b)15. The
more proximal binding of heme to this region of the receptor that
interacts with the CoRNR box peptide (relative to STL1267 binding)
leads to heme itself sterically hindering formation of the anti-parallel βsheet that is observed in the STL1267-bound receptor.
Given the distinct interactions that the synthetic ligand displays in
the LBD relative to heme, we sought to conﬁrm the binding mode by
mutating key amino acid residues that interact directly with STL1267 to
alanine (i.e., Phe497, Phe443, Phe480, Phe439, Phe484, and Phe488
(Fig. 4d). We assessed the impact of these mutations in a cell-based
cotransfection model where we measured the ability of the REV-ERBα
to recruit a fragment of the NCoR1 corepressor. Plasmids directing the
expression of WT or mutant Gal4DBD- full length REV-ERBα fusion and
NCoR1-VP16 fusion protein were transfected into HEK293 cells with a
Gal4UAS luciferase reporter stably integrated. As shown in Fig. 6a,
STL1267 effectively induces interaction between REV-ERBα and NCoR
and mutation of nearly all the amino acid residues that were hypothesized to be critical for STL1267 binding (F497A, F443A, L480A,
F439A, and F484A) resulted in loss or severe reduction in activity.
Surprisingly, one mutation (F488A) led to an impressive improvement
in potency and efﬁcacy in REV-ERBα’s NCoR recruitment activity
(Fig. 6a). The removal of the bulkier Phe488 sidechain may allow for
the ligand binding pocket to wrap around the ligand more tightly,
which may explain the higher activity of this mutant REV-ERB. These
data indicate that the residues identiﬁed in the crystal structure as
critical for STL1267 binding are indeed critical for STL1267 regulated
activity of the receptor.

We performed molecular dynamics (MD) simulations of wild-type
REV-ERBα and the mutant F488A bound with STL1267 and NCOR ID1
peptide to develop a hypothesis as to why the F488A mutation led to a
gain of function. In the wild-type simulations, STL1267 binding to the
receptor structure was stable with the biphenyl ring moving slightly
deeper inside the LBP (Fig. 6b). STL1267 maintained interactions with
Phe497, Phe443, Phe480, and Phe439 where the calculated distances
probabilities between STL1267 and interacting amino acid side chains
ranged between 5 and 7 Å (Fig. 6c). STL1267 lost its interaction with the
phenyl group of Phe488 in accordance with the mutagenesis experiments where the STL1267 potency increased in the Phe488A mutant.
The distance probability between STL1267 and Phe488 in the MD
simulations was 10 Å (Fig. 6c). The interaction of STL1267 and Phe488
is lost during the simulations because the phenyl group of Phe488
ﬂipped outside of the LBP and formed hydrophobic interactions with
side chains of amino acid residues Phe521, Val490 and Leu505 (Supplementary Fig. 4). The loss of Phe488 interaction with STL1267 was
compensated by STL1267 interactions with the methyl groups of
Met520 and Val495 side chains, which occupied the vacant space
created by the side chain of Phe488 ﬂipping out of the LBP (Fig. 6b). In
the molecular dynamics simulations of the F488A mutant, STL1267
maintained similar pattern of interactions with Phe497, Phe443,
Phe480, Phe439, Met520, and Val495 (Supplementary Fig. 5). We also
utilized Molecular Mechanics Generalized Born Surface Area (MM/
GBSA)33 to qualitatively estimate the binding free energies of STL1267
to the wild-type and mutant REV-ERBα receptor (Supplementary
Table 4). In the case of the F488A mutant, both the enthalpy (ΔH) and
entropy (ΔS) contribution of STL1267 to the total binding free energy,
ΔG, were more favorable (ΔG value is −24.4 Kcal/mol for the mutant
versus a ΔG value of −20.8 Kcal/mol for the wild type). Thus, the
simulations suggest that the aromatic side chain of Phe488 is not
favorable for ligand binding at this contact point of the ligand, rather
the methyl groups of nearby amino acid side chains were preferred for
ligand interaction. Therefore, it is not surprising that mutation of
Phe488 to alanine resulted in gain of STL1267 potency as alanine has
smaller size side chain providing additional vacant space for the
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nearby amino acid side chains of M520 and Val495 to interact freely
with the ligand.
Another interesting insight revealed by the MD simulations of
REV-ERBα/STL1267/NCoR ID1 complex is the increased ﬂexibility of the
β-sheet regions of NCoR (amino-terminal) and REV-ERBα (carboxyterminal) as observed in the MD simulations trajectory (Supplementary Movie 1 and Supplementary Data 1 and 2) and indicated by
increased ﬂuctuations (RMSF) of the β-sheets region (RMSF~ 6–9 Å)
while the N-CoR α-helical region was dynamically more stable
(RMSF < 3 Å) (Supplementary Fig. 7). These results infer that the NCoR
α-helical region is more important for interaction with REV-ERBα. This
is in accordance with previously reported structural and mutagenesis
data where alanine mutations of the NCoR α-helical residues, Ile2055,
Ile2058, Ile2059 (ICQII motif) abolished the interaction with REV-ERBα,
whereas mutations in the extended N-terminal β-sheet (LADH extension), residues His2046, Leu2048, Leu2051, and His2054 had little
effect30.

Discussion
The porphyrin, heme, was identiﬁed as a physiologically relevant
ligand for REV-ERBα11,12 and REV-ERBβ11 in 2007. Prior to this discovery,
the REV-ERBs were believed to be constitutive repressors of expression
of their target genes; however, these constitutive effects are likely due
to the constitutive availability of heme rather than ligand-independent
activity of REV-ERB. Mutation of amino acid residues within the LBP of
REV-ERB that are responsible for coordinating the iron ion within the
porphyrin ring eliminate the ability of REV-ERB to bind to heme and
render the receptor unable to modulate gene transcription11,12. The
observation that the REV-ERBs are ligand-dependent transcriptional
repressors led to signiﬁcant efforts to develop agonists and antagonists that could be used as chemical tools to modulate the activity of
these receptors in cell- and animal-based models given that the REVERBs regulate myriad physiological pathways involved in many disease
processes13,34–36. These efforts led to the development of a number of
compounds that are now used as standard pharmacological chemical
tools targeting REV-ERBs including the agonists GSK411216,37, SR90096,
and the antagonist SR827838. Although these chemical tools, in combination with REV-ERB genetic loss of function models, have been
effective in determining the potential therapeutic value of synthetic
REV-ERB ligands improvements in the pharmacodynamic and pharmacokinetic properties of such ligands has been slow to progress. Any
efforts to develop synthetic ligands based on the natural porphyrin
ligand for REV-ERB have been avoided due to heme binding to a vast
array of proteins and the prediction that REV-ERB speciﬁcity with such
a chemical scaffold will be insurmountable.
Crystal structures of the apoREV-ERBα30 and -β31 LBDs have been
determined, but the only structures of REV-ERB LBD bound to ligands
are of porphyrins ((heme14,15 (agonist) or cobalt protophorphyrin32
(antagonist)). Given the expected unique nature of porphyrins binding
within the LBD of REV-ERB relative to more drug-like synthetic ligands,
such as histidine/cysteine residues coordinating metal ions, these
crystal structures have not been very informative about how nonporphyrin ligands may bind and have not been useful from the perspective of rational drug design. Our assessment of the activity of a
high-afﬁnity non-porphyrin REV-ERB agonist, STL1267, enabled our
efforts to develop a radioligand binding assay for REV-ERB as well as to
determine the crystal structure of a non-porphyrin agonist bound to
the LBD of REV-ERBα. In addition to being considerably more potent
(STL1267 REV-ERBα Ki = 0.16 μM vs. 0.68 μM for SR9009), STL1267
was also much more efﬁcacious than SR9009 in biochemical and cellbased assays detecting recruitment of NCoR. This appeared to translate into greater maximal efﬁcacy of STL1267 regulation of target REVERB genes in many cases.
Although the STL1267/REV-ERBα LBD/NCoR1 ID1 peptide crystal
structure showed similar global structure to other REV-ERB LBD
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structures, there were two very important distinctions. Firstly, the
mechanism of how STL1267 bound to the LBD was very distinct from
that described for the porphyrin ligands. Although heme and STL1267
displayed some overlap in the regions occupied within the LBP of REVERBα, heme occupied a region much more proximal to helix 11 and the
corepressor binding surface. In fact, heme was partially solvent
exposed in this region. Water molecules occupied the LBP of the heme
bound LBD where they interacted with the carboxylic acid moieties of
heme. The central iron ion was also coordinated by a key histidine and
a key cysteine residue. In contrast, STL1267 bound to the LBD in a
deeply buried hydrophobic pocket much more distal to helix 11 where
the interactions with the residues within the LBP were hydrophobic in
nature. Even with these distinctions in their modes of binding, both
agonists led to effective binding of the NCoR CoRNR box ID1 peptide.
However, this leads to the second distinction in the structures. Part of
the heme molecule actually extends out of the point of entry into the
LBP of REV-ERBα, which leads to an altered structure of the NCoR1
peptide. Although the core α-helical I/LxxI/LI component of the peptide was identical in both structures and docked with the “coactivator”
binding cleft of the LBD, the amino-terminal extension of the CoRNR
box peptide formed an antiparallel β-sheet with carboxy-terminal
component of helix 11 in the STL1267-bound structure only. In the
heme-bound structure, the ligand heme extended out of the ligand
binding pocket interfering with the ability of helix 11 to form such an
anti-parallel β-sheet structural motif and the residues that formed this
motif in the NCoR peptide were not resolved in the structure. This
suggests that STL1267-bound receptor leads to a distinct complex
mode of interaction with the corepressor than heme-bound receptor.
Although it is currently unclear, such additional interactions between
REV-ERB and corepressor induced speciﬁcally by STL1267 may yield
unique pharmacological actions (e.g. altered efﬁcacy or modulator-like
proﬁle).
We compared the activity of STL1267 to SR9009 and given a
recent study17 indicating that SR9009’s toxicity (independent of
REV-ERB activity) may preclude its use as a chemical tool. We
treated either C2C12 cells or HepG2 cells with increasing concentrations of the two drugs and examined toxicity by crystal
violet staining. Dierickx et al. reported severe SR9009 toxicity in
mouse embryonic stem cells (ESCs) independent of REV-ERBα/β
expression as well as in a range of other cell types17. The authors
also observe decreases in mitochondrial respiration with SR9009
in ESCs, which aligns with the ATP-dependent endpoint of their
cellular viability assays17. These observations are in contrast to
those where SR9009 increased mitochondrial mass and membrane potential in C2C12 cells5 (5 μM) and enhanced mitochondrial respiration in retinal pigment epithelial cells39 (1 μM). Thus,
these effects appear to be very cell type speciﬁc as well as
dependent on the dose of SR9009 used as we observed in C2C12
vs. HepG2 cells (Fig. 2a, b). In terms of reduction in cell viability,
C2C12 cells were much more sensitive to both drugs relative to
HepG2 cells, but in general, STL1267 had much reduced effect on
cellular viability in general. The availability of a REV-ERB agonist
with greater potency than SR9009 with a distinct chemical scaffold provides an important tool in REV-ERB pharmacology to
allow for examination of potential REV-ERB speciﬁcity issues. One
would expect that off-target effects would not necessarily be
shared between two distinct chemical scaffolds and comparison
of the effects of these drugs may help to deﬁne which are REVERB driven. The lack of complete REV-ERBα/REV-ERBβ KO mouse
model to evaluate SR9009 has led to some controversy as to the
speciﬁcity of this compound. In many cases, SR9009 gain-offunction has been compared to REV-ERBα genetic loss-of-function
(KO) or gain-of-function phenotypes (overexpression) to correlate the potential role of REV-ERB as well as potential therapeutic
value of pharmacological targeting this receptor2–6,24–27,40–43. In
8

Article
other cases, SR9009’s efﬁcacy in WT mice/cells was compared to
efﬁcacy in the REV-ERBα KO mouse model or cellular REV-ERBα
KD to determine if there is a degree of efﬁcacy lost1,2,44–47. Another
issue that has arisen is the use of ﬂoxed allele KO mice as models
to examine receptor speciﬁcity of drugs such as SR9009. In many
cases these models produce hypomorphs that represent signiﬁcantly reduced expression of the receptor, but not complete
loss. For example, when we assessed the RNA-seq data obtained
from hepatocytes (treated with SR9009 or vehicle) from Reverbα/β ﬂ/ﬂ ﬂ/ﬂ mice treated in vivo with AAV-Cre (tail vein injection)17
we observe that 39% of genes identiﬁed as REV-ERB regulated
genes based on comparison of WT vs Rev-erbα/β ﬂ/ﬂ ﬂ/ﬂ DKO
hepatocytes were still regulated by SR9009 in the Rev-erbα/β ﬂ/ﬂ ﬂ/ﬂ
DKO hepatocytes48. Although one might expect to observe some
degree of overlap in SR9009-regulated genes that are not REVERB-dependent with those that are REV-ERB-dependent, a 39%
overlap is more consistent with a hypomorph phenotype. Yet
another issue to consider when using this type of gene expression
analysis as indicator speciﬁcity of a drug (particularly for a tool
compound), one must consider that the agents are xenobiotics
and pharmacokinetic parameters must be considered including
genes of the xenobiotic response which will likely be regulated to
a signiﬁcant degree independent of the intended target. The
addition of STL1267 to the chemical tools that can be used to
probe REV-ERB function will aid in the assessment of speciﬁcity
as well.

Methods
HEK293 and HEK293 UAS-luc
Prior to use in co-transfection assays, the human embryonic kidney
(HEK293) cell line (ATCC, CRL-1573) was cultured in 10% FBS DMEM at
37 °C in a humidiﬁed atmosphere of 5% CO2. HEK UAS-luc cells contain
a plasmid that is resistant G418 (Geneticin). This antibiotic was added
to the media of these cells to preserve the HEK UAS-luc cell line.

Cell culture
The human hepatocellular carcinoma cell line, HepG2 cells (ATCC HB8065), were cultured in 10% FBS 1% L-Glu MEM at 37 °C in a humidiﬁed
atmosphere of 5% CO2. Prior to RNA extraction cells were treated with
either DMSO or REV-ERB agonist for 24 h. The C2C12 proliferating
mouse myoblast cells (ATCC, CRL-1772) were cultured in 10% FBS
DMEM at 37 °C in a humidiﬁed atmosphere of 5% CO2. Prior to RNA
extraction cells were treated with either DMSO or REV-ERB agonist for
24 h. Prior to crystal violet cytotoxicity assay, cells were treated with
either DMSO or REV-ERB agonist for 48 h.

Radioligand binding assays
For radioligand displacement assays, an 11-point serial dilution of cold
REV-ERB agonist, STL1267 or SR9009, was prepared in buffer (20 mM
potassium phosphate pH 7.4, 50 mM KCl, 0.005% TWEEN20, 1 mM
DTT). On top of the drug, a solution of protein/radioligand mix was
added to the assay plate. The ﬁnal concentration of the protein/radioligand mix in the plate were as follows: 80 nM 3H-1267/96.9 μCi and
120 nM (0.57 μg/well) “heme” REV-ERBα. YSI Copper Ni SPA beads
were added to a ﬁnal concentration of 240 μg/well. The contents of the
plate were mixed on a shaker (400 rpm) for 20 min and then allowed to
sit for 10 min prior to read-out of scintillant emission. Data were normalized by taking the average of the DMSO value per plate (the maximum binding) and dividing all the test values from the same plate by
this DMSO average. The normalized values were transformed using
X = Log(X) in Prism. The IC50 was derived from the transformed values
using “One site – Fit logIC50” in the “Binding – Competitive” folder.
The Ki was derived from the transformed values using “One site – FitKi”
in the “Binding – Competitive” folder. Radioligand binding assays
intended to determine 1267 speciﬁcity were carried out by the NIMH
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Psychoactive Drug Screening Program in accordance with the PDSP
protocol (https://pdsp.unc.edu/pdspweb/content/PDSP%20Protocols
%20II%202013-03-28.pdf).

FRET
A serial dilution of REV-ERB agonist, STL1267 or SR9009, was prepared
in buffer (0.1% Triton, 5 mM DTT, PBS). Histidine tagged REV-ERBα/β
complexed with heme was added to each well to a ﬁnal concentration
of 4 nM. NCoR ID1 ﬂuorescein (ref#PV4622, Batch# 1797468C) was
added to each well to a ﬁnal concentration of 150 nM, and terbium antihistidine (ref#PV5895, batch 1730002B) was added to a ﬁnal concentration of 1 nM. Mixture was incubated at room temperature on an
orbital shaker for 1 h at 200 rpm. The lanthascreen assay protocol
(Dual PMT, excitation 340 nm, dual emission 495/520, Gain 110/110)
was used to read the plate.

Co-transfection assays
The NCoR-Vp16 plasmid and REV-ERBα/β-FL GAL4-DBD wild-type or
point mutation plasmids were incubated with the transfection agent,
Lipofectamine 2000. GFP plasmid was also in the transfection mix to
conﬁrm transfection efﬁciency. HEK cells were plated in 10 cm dishes
for western blot analysis, and HEK UAS-luc cells were plated in 96 well
plates for luciferase assay analysis. Prior to cellular adherence, transfection mix was added. The cells and transfection mix were incubated
at 37 °C in a humidiﬁed atmosphere of 5% CO2. The transfection
incubation lasted overnight for luciferase assays and 48 h for protein
isolation/western blot analysis. For luciferase assays, REV-ERB agonists
were added in an 11-point serial dilution the day following overnight
transfection. Cells were incubated with the compound for 24 h, prior
to luciferin addition and luminescence read out.

Crystal violet cytotoxicity
Proliferating C2C12 and human peripheral blood monocytes were
treated for 48 h with indicated concentrations of REV-ERB agonist or
vehicle (DMSO). Media was removed, and cells were incubated with
0.5% crystal violet solution for 20 min at room temperature with mild
agitation. Cells were washed four times with tap water before being air
drying overnight. Cells were incubated in methanol for 20 min with
mild agitation. Absorbance was read at 570 nm, and readings were
normalized to vehicle (DMSO) treated cells.

RNA extraction
Mouse tissue was homogenized using a bullet blender. DNA/protein
was removed by phase separation using BCP/chloroform. The supernatant (RNA containing fraction) was collected, and RNA was precipitated using isopropanol. The RNA pellets were washed with 75%
ethanol and resolubilized in RNAse free water. The purity of the RNA
was tested by agarose gel prior to cDNA synthesis. Total RNA was
harvested from HepG2 and C2C12 using the RNeasy mini kit according
to manufacturer’s instructions (Qiagen).

Quantitative PCR
Isolated RNA was reverse transcribed into cDNA using the
qScriptTMcDNA Synthesis kit according to the manufacturer’s instructions (QuantaBio). Quantative PCR (qPCR) was performed on a
QuantStudioTM 6 Flex or QuantStudioTM 7 Flex (Life Technologies)
using SYBRTM Select Master Mix (Applied BioSystems) with select primers (Table S2). Gene expression was normalized to Ppia for all data
sets. Oligonucleotide sequences are provided in Supplementary
Table 2.

Mouse studies
All in vivo studies were performed using the ARRIVE guidelines and
approved by the Washington University IACUC. C57Bl/6J mice (male;
6–8 weeks of age) maintained at 12:12 h light;dark, 22 °C, 40–60%
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Gene of human Rev-erbα (P281-Q614) deleted from region P324-P424
was cloned into a peT-15b vector. The protein was produced in bacteria
in fusion with a (His)6- tag at the N-terminus with a thrombin cleavage
site in between. The protein was overproduced in Escherichia coli
BL21(DE3) strain in auto-induction medium at 25 °C during 2h30.
Bacterial cells from 6 L were harvested by centrifugation and resuspended in lysis buffer (25 mM Na Hepes pH7.5, 150 mM NaCl, 2 M
Urea). After 10-fold protein dilution in buffer A (25 mM Na Hepes
pH7.2, 0.5 mM EDTA, 5 mM dithiotreitol (DTT), 5% glycerol) additional
puriﬁcation was performed with an ion exchange chromatography
(HiTrap Q FF 5 ml) equilibrated in buffer A. A 30 CV-gradient from 0 to
1 M NaCl was applied, and protein eluted at a NaCl concentration of
around 150 mM.

(1 µs) using Amber1849. Analysis plots on the protein alpha carbons
validating protein folding and the stability the simulations, such as
root mean square deviation (RMSD), solvent accessible surface area
(SASA), radius of gyration (Rg) is provided in Supplementary Fig. 6.
Coordinates for the wild- type and mutant REV-ERBα/NCoR ID1/
STL1267 were obtained from the Xray structure. First, energy minimization was carried out using the steepest descent and conjugate
gradient methods while keeping the ligand constrained. The constraints were removed and then each system was energy minimized
entirely. The LeaP module was used to neutralize and solvate the
complexes using an octahedral water box of TIP3P water molecules.
The FF14SB forceﬁeld parameters were used for all receptor residues
and the general amber force ﬁeld was applied to the ligand50. Nonbonded interactions were cut off at 10.0 Å, and long-range electrostatic interactions were computed using the particle mesh Ewald
(PME). Ligands were modeled using Maestro and pictures were generated using UCSF Chimera and Maestro51. After energy minimization,
the system was gradually heated with the Langevin thermostat to
300 K over 30 ps at constant volume using 1 fs time step. Initial velocities were sampled from the Boltzman distribution while keeping
week restraints on the solute and the ligand. The system was then
equilibrated in the isothermal-isobaric ensemble (NPT), at 300 K, using
constant pressure periodic boundary with an average pressure of
1 atm. Isotropic position scaling was used to maintain the pressure with
a relaxation time of 2 ps. The SHAKE algorithm was used to keep bonds
involving H atoms at their equilibrium length. Two fs time step was
used for the integration of Newton’s equations. Production simulations were performed on GPUs using the CUDA version of Particle
Mesh Ewald Molecular Dynamics (PMEMD) for one microsecond, 1 µs
MD52. Distances were calculated between the center of mass of two
selected residues. Distances, Rg, RMSD and SASA, RMSF calculations
were calculated using CPPTRAJ53. The entropy and enthalpy calculations were performed using normal mode analysis approximation and
MM-GBSA algorithm implemented in AMBER18 (Supplementary
Table 4). Trajectory clustering as well as pictures and MD simulations
movie were generated using UCSF Chimera54. Plots were generated
using Gnuplot.

Protein crystallization and structure reﬁnement

Statistical analysis

Prior to crystallization, 2 molar equivalents of nuclear receptor
corepressor 1(NCOR1) peptide (2045-THRLITLADHIAQIITQDFAR2065) were added to REV-ERBα and the complex was concentrated to 5 mg/ml ultraﬁltration. Crystallization experiments
were carried out at 22 °C using the sitting drop vapor diffusion
method in 96-well plates (300 nl protein solution + 300 nl reservoir) using Innovadyne nanodrop robot. Crystals grew in 80 mM
Na Hepes pH7.5, 200 mM proline, 8% glycerol, and 18% PEG3350.
Apo crystals appeared in 24 h. For soaking experiments, apo Reverbα/NCOR1 crystals were transferred to new drops of crystallization condition supplemented with 10−3M of STL1267 (M. wt
322.7 Da) for one month. After soaking, crystals were cryoprotected with 23% of glycerol added to the crystallization condition and ﬂash frozen in liquid nitrogen. X-ray diffraction tests
and data collections were performed on PROXIMA-1 beamline
(Wavelength 0.978 Å) at SOLEIL synchrotron. X-ray data were
processed with Autoproc/Staraniso. Molecular replacement and
structure reﬁnement were performed with Buster using PDB
3N00 as starting model. Ligand dictionary was generated with
Grade. Final model quality was monitored by H (98.14% of residues in favored region).

Unless otherwise speciﬁed, statistical signiﬁcance was determined by
subjecting mean values per group to two-sided Student’s t test. A value
of p < 0.05 is considered statistically signiﬁcant.

Molecular modeling

3.

humidity. Mice were injected IP with 50 mg/kg STL1267 (n = 3–4 per
group) or vehicle (10% DMSO, 12% TWEEN80, PBS) (n = 3–4 per group).
Mice were weighed immediately following the injection and were
weighed again immediately after sacriﬁce. Mice were fasted started at
the time of injection. For tissue collection, three STL1267-injected mice
were sacriﬁced at 1 h post-injection, and three more were sacriﬁced at
3 h post-injection. At 8 h and 12 h post-injection, six mice from each
treatment group were taken down and tissue was collected. The tissues
collected at all four time points include plasma, white adipose tissue,
brain, liver, and skeletal muscle (quadriceps). RNA was extracted from
liver samples at T = 12 h post-injection for analysis of REV-ERB target
genes. Tissue samples were sent to Charles River Laboratories for LCMS/MS detection of STL1267. For LC-MS/MS analysis, tissue samples
were homogenized using bead beater in acetonitrile:water (3:1) at
250 mg/ml. Naïve tissues were used to prepare standard, quality control, and blank samples in tissue matrix. Homogenized tissue or plasma
samples were kept on ice and spiked with internal standard. Analytes
were extracted using protein precipitation techniques with acetonitrile
and samples were then analyzed using a SCIEX Triple Quad 5500+
system – QTRAP ready linked to an ExionLC AD-HPLC system. Data
analysis was performed using SCIEX OS software.

Expression and puriﬁcation of REV-ERBα LBD for X-ray
crystallography

Molecular dynamics simulations were performed on the wild-type and
F488A mutant of REV-ERBα/NCoR ID1/STL1267. Molecular dynamics
simulations were performed on each system for one microsecond
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Reporting summary
Further information on research design is available in the Nature
Portfolio Reporting Summary linked to this article.

Data availability
The data that support this study are available from the corresponding
authors upon reasonable request. Structural data have been deposited
in the Protein Data Bank (PDB) under accession code 8D8I (REV-ERBα
LBD and STL1267). Data underlying Fig. 2; and Supplementary Fig. 2 are
available as a Source Data ﬁle. Source data are provided with
this paper.
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